Adagio Medical Holdings, Inc. filings document a public medical-device issuer developing catheter ablation systems for cardiac arrhythmias. Its Form 8-K reports include operating and financial results, business updates, clinical-study announcements, FDA IDE-related events, and press releases concerning the vCLAS® Ventricular Ablation System and Ultra-Low Temperature Ablation technology.
The company’s proxy and governance filings cover shareholder voting matters, director nominations, annual-meeting results, material agreements, governance practices, and capital-structure disclosures. Filings also identify ADGM common stock as Nasdaq-listed and classify the company as an emerging growth company for Exchange Act reporting purposes.
Adagio Medical Holdings, Inc. reported that director James L. Cox received a grant of a non-qualified stock option for 30,000 shares of common stock on June 16, 2026. The option has an exercise price of $0.7103 per share and expires on June 16, 2036. It vests in equal monthly installments over one year, with 1/12 of the shares vesting after each month of continuous service beginning on the vesting commencement date of June 16, 2026. Following this grant, Cox holds 30,000 option shares directly.
Adagio Medical Holdings, Inc. reported that director Sandra A. Gardiner received a grant of 30,000 non-qualified stock options on June 16, 2026 under the Non-Employee Director Compensation Policy and 2024 Equity Incentive Plan. The options have an exercise price of $0.7103 per share and expire on June 16, 2036. They vest in equal monthly installments over one year, with 1/12 of the underlying shares vesting at the end of each month of continuous service after the June 16, 2026 vesting commencement date, resulting in 30,000 options held directly after this grant.
Adagio Medical Holdings, Inc. director Orly Mishan received a grant of 100,000 non-qualified stock options on June 16, 2026 under the company’s Non-Employee Director Compensation Policy and 2024 Equity Incentive Plan. The options have an exercise price of $0.7103 per share and expire on June 16, 2036. They vest in equal monthly installments over one year, with 1/12 of the underlying shares vesting after each month of continuous service following the vesting commencement date of June 16, 2026.
Adagio Medical Holdings, Inc. reported that director Timothy P. Moran received a grant of 30,000 non-qualified stock options on 2026-06-16. The options have an exercise price of $0.7103 per share and expire on 2036-06-16.
The grant was made under the company’s Non-Employee Director Compensation Policy and 2024 Equity Incentive Plan. The option will vest in equal monthly installments over one year, with 1/12 of the underlying shares vesting at the conclusion of each month of continuous service after the vesting commencement date of 06/16/2026. Following this grant, Moran holds 30,000 derivative securities directly.
Adagio Medical Holdings, Inc., a cardiac ablation technology company, reported continued operating losses and tight liquidity for the quarter ended June 30, 2026. Cash and cash equivalents were $7.7 million, down from $17.1 million at December 31, 2025, while total assets declined to $33.9 million. Convertible notes payable measured at fair value increased to $24.8 million, and total liabilities of $34.3 million exceeded assets, resulting in stockholders’ deficit equity of $(0.4) million.
The company generated no revenue in the three and six months ended June 30, 2026 and 2025. Net loss was $6.7 million for the quarter (vs. $3.9 million a year earlier) and $13.7 million for the first six months of 2026 (vs. $11.7 million in 2025). Net cash used in operating activities for the six-month period was $9.4 million, following $11.9 million used in the prior-year period.
The company highlights development of its vCLAS Ventricular Ablation Systems based on its Ultra-Low Temperature Ablation platform. It submitted a Premarket Approval application to the FDA in May 2026 after completing enrollment and six‑month pivotal results in its U.S. IDE trial, and holds FDA Breakthrough Device designation and a European CE Mark for the vCLAS system. Management discloses substantial doubt about the company’s ability to continue as a going concern within one year, noting current cash is expected to fund operations only into the fourth quarter of 2026 and that additional equity, debt or strategic financing and cost reductions are planned but not assured.
Adagio Medical Holdings, Inc. reported second quarter 2026 results and highlighted progress in its ventricular tachycardia program. Management cited an inflection point driven by favorable -VT pivotal data, submission of the vCLAS Ventricular Ablation System PMA to the FDA in May 2026, IDE approval to evaluate the next-generation vCLAS Ultra catheter, and CE-marked commercial availability of vCLAS for monomorphic VT in Europe and select other geographies.
For the quarter ended June 30, 2026, revenue was $0. Cost of revenue was nil versus $0.3 million a year earlier due to a pause in commercial activity in Europe. Research and development expenses rose to $2.5 million from $2.0 million, and selling, general and administrative expenses were $2.5 million versus $2.4 million. Net loss widened to $6.7 million, or $(0.30) per basic share, compared with $3.9 million, or $(0.26) per basic share, in 2025, driven in part by a $1.2 million unfavorable fair value adjustment on convertible notes. Cash and cash equivalents were $7.7 million as of June 30, 2026, with total liabilities of $34.3 million and stockholders’ deficit of $0.4 million.
Sio Capital Management, LLC, a Delaware limited liability company and registered investment adviser, reported beneficial ownership of 698,989 shares of Adagio Medical Holdings, Inc. common stock as of June 30, 2026. These shares represent 3.15% of Adagio’s common stock, based on 22,210,459 shares outstanding as of May 8, 2026.
Sio has shared voting and dispositive power over all 698,989 shares through affiliated funds for which it serves as investment adviser, and no sole voting or dispositive power. The filing notes that Sio GP, LLC and Michael Castor may be deemed beneficial owners but expressly disclaim such beneficial ownership. The position is reported as ownership of 5 percent or less of the class.
Adagio Medical Holdings, Inc. filed an amendment to its Annual Report for the year ended December 31, 2025 to replace Exhibits 31.1 and 31.2. The change corrects an inadvertent omission of language in paragraph 4 of the principal executive and financial officer certifications required under Section 302 of the Sarbanes-Oxley Act.
The amendment does not alter any other part of the original Annual Report and does not update disclosures for subsequent events. As of June 30, 2025, the aggregate market value of common stock held by non-affiliates was $7.0 million, and as of March 23, 2026, there were 22,210,459 common shares outstanding.
Adagio Medical Holdings, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. Stockholders representing 16,069,984 shares, or 72.35% of the 22,210,459 shares outstanding as of the record date, were present or represented by proxy.
Two director nominees were elected to serve until the 2029 annual meeting. Orly Mishan received 11,930,745 votes for and 1,396,139 withheld, with 2,743,100 broker non-votes. Sean Salmon received 13,322,425 votes for and 4,459 withheld, with 2,743,100 broker non-votes.
Stockholders also ratified the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 16,055,195 votes for, 14,081 against, and 708 abstentions.
Adagio Medical Holdings, Inc. reported that Nasdaq has notified the company its common stock no longer meets the Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement. The stock has closed below $1.00 per share for the past 30 consecutive business days.
The company has 180 calendar days, until December 9, 2026, to regain compliance while its shares continue trading on the Nasdaq Capital Market. Compliance would be restored if the bid price closes at or above $1.00 for at least ten consecutive trading days.
If compliance is not regained by that date, Adagio may qualify for a second 180‑day period if it meets other Nasdaq Capital Market initial listing standards and indicates an intent to regain compliance, potentially through a reverse stock split. Failure to satisfy these conditions could result in delisting of its common stock.